健民龙牡品牌怎么样 申请店铺

我要投票 健民龙牡在中草药行业中的票数:446 更新时间:2025-08-20
健民龙牡是哪个国家的品牌?「健民龙牡」是 健民药业集团股份有限公司 旗下著名品牌。该品牌发源于湖北,由创始人刘勤强在1993期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力健民龙牡品牌出海!将品牌入驻外推网,定制健民龙牡品牌推广信息,可以显著提高健民龙牡产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

健民龙牡怎么样

龙牡壮骨颗粒是武汉健民集团旗下一个有着近20年辉煌历史、创造了中国医药界长盛不衰奇迹的知

名品牌,整整抚育了中国两代儿童的健康成长。
龙牡壮骨颗粒的的主要药材(如茯苓、麦冬等)都直接选用武汉健民集团专门建设的GAP药材种植

基地的原料,药材天然地道。生产过程中的每个环节、每道工序都有严格的质控标准,做到了“不合

格的原料不进厂,不合格的半成品不转到下道工序,不合格的产品不出厂”。

龙牡壮骨颗粒问世18年,畅销了18年,累计60亿袋的产量。“龙牡”的面世和畅销,创造了令人惊叹

的市场业绩和品牌价值,也使得武汉健民——一个有着悠久历史、而却依然年轻的企业焕发出勃勃的

生机,从此享誉长城内外,大江南北。

“龙牡”,曾经独领儿童补钙产品市场的风骚。而如今,它却受到了来自其它同类竞品的强力竞

争和挑战,面临着市场份额被不断蚕食和瓜分的严峻局面。

抚育了中国整整二代人的茁壮成长。

1985年在武汉市儿童医院出生,填补了我国以中药为主体,防治小儿佝偻病的空白;

1990年被收载入湖北省药品标准;

1992年被列为国家唯一的补钙一级中药保护品种;

1993年被中国儿童保护中心推荐为最佳小儿补钙、促进钙质吸收药品;

1994年被全国佝偻病防治协作组列为首推中成药;

1995年被收载入卫生部药品标准;

1999年被列为国家基本药物;

2000年被中国药典2000版收载;

2002年被列为国家处方药与非处方药(OTC)双跨品种;

同年,被《中医儿科学》(新世纪全国高等中医院校规划教材)收载。

武汉健民为中国医药工业50强企业,集团股份有限公司是国家重点高新技术企业、全国中成药小儿用药生产基地、全国重点中药企业。集团的前身是中国最古老的四大中药名店之一的叶开泰药店,距今已有近四个世纪的历史,现拥有十余个子公司,集生产、科研、经贸于一体,年生产能力近十亿元。

改革开放以来,集团公司以振兴民族医药为己任,积极推进企业改革,不断探索新的管理体制和运行机制,大力提高企业创新能力,促进了公司的全面发展,企业获得了比以往任何时候都好的社会效益和经济效益,创造了国有企业稳健经营的奇迹,综合实力跻身于全国企业500强和行业50强。近几年,集团大力实施科技兴业战略,确立了坚持以中药研发、生产和销售为主业,重点开发市场急需的小儿用药,老年用药和重大疑难病症用药,构建以中药现代化、产业化为基础,以高新技术药品为支撑的科技先导型医药集团。

目前,健民集团已成功地研制和开发出以龙牡壮骨颗粒、健民咽喉片、健脾生血颗粒、便通胶囊、慢肝宁胶囊为代表的系列产品,形成了集团蔚为壮观的"名牌林",产品行销全国,远销东南亚及欧美国家和地区。集团在近些年中相继荣获"全国质量效益型先进企业"、"全国中药行业优秀企业"、"全国五一劳动奖状"等称号,被誉为"搞好搞活国有企业的一面旗帜","健民"商标亦荣获"中国驰名商标"称号。一个以中药产业为基础,以高新科技为特征的健民集团必将在新的世纪里创更辉煌的业绩,谱写出振兴国药的优美乐章。

Longmu Zhuanggu Granule is a well-known brand under Wuhan Jianmin group, which has a glorious history of nearly 20 years and has created a long-lasting miracle in the field of Chinese medicine. It has nurtured the healthy growth of two generations of children in China. The main medicinal materials of Longmu Zhuanggu granules (such as Poria cocos, Ophiopogon japonicus, etc.) are directly selected from the gap medicinal materials planting base specially built by Wuhan Jianmin group, which are natural and authentic. There are strict quality control standards for each link and process in the production process, so that "unqualified raw materials are not allowed to enter the factory, unqualified semi-finished products are not transferred to the next process, and unqualified products are not allowed to leave the factory". Longmu Zhuanggu granules have been produced for 18 years and have been popular for 18 years, with a total output of 6 billion bags. The appearance and best-selling of "Longmu" has created amazing market performance and brand value, and also made Wuhan Jianmin, an enterprise with a long history but still young, full of vitality. Since then, it has been famous inside and outside the Great Wall, North and south of the river. "Longmu" once led the market of children's calcium supplement products. But now, it is faced with strong competition and challenge from other competitors, and the market share is constantly eroded and divided. He nurtured two generations of Chinese people. Born in Wuhan children's Hospital in 1985, it has filled in the blank of prevention and treatment of rickets in China with traditional Chinese medicine as the main body; in 1990, it was included in the drug standard of Hubei Province; in 1992, it was listed as the only one level of protection of traditional Chinese medicine for calcium supplement; in 1993, it was recommended as the best drug for children's calcium supplement and calcium absorption by China children's protection center; in 1994, it was recommended by the National Coordination Group for prevention and treatment of rickets It was listed as the first Chinese patent medicine; in 1995, it was listed in the drug standard of the Ministry of health; in 1999, it was listed as the national basic drug; in 2000, it was listed in the 2000 edition of the Chinese Pharmacopoeia; in 2002, it was listed as the national prescription medicine and over-the-counter medicine (OTC) double cross varieties; in the same year, it was listed in the pediatrics of traditional Chinese medicine (the textbook for the planning of the national higher education of traditional Chinese medicine in the new era). Wuhan Jianmin is one of the top 50 enterprises in China's pharmaceutical industry. The Group Co., Ltd. is a national key high-tech enterprise, a national production base of Chinese patent medicine for children and a national key Chinese medicine enterprise. The group's predecessor is Ye Kaitai drugstore, one of the four oldest famous traditional Chinese medicine stores in China. It has a history of nearly four centuries. Now it has more than ten subsidiaries, integrating production, scientific research and economic and trade, with an annual production capacity of nearly one billion yuan. Since the reform and opening up, the group company has taken the revitalization of national medicine as its own duty, actively promoted the enterprise reform, constantly explored new management system and operation mechanism, vigorously improved the innovation ability of the enterprise, promoted the overall development of the company, obtained better social and economic benefits than ever before, created a miracle of steady operation of state-owned enterprises, and its comprehensive strength ranks among Top 500 enterprises and top 50 industries in China. In recent years, the group has vigorously implemented the strategy of developing industry through science and technology, established a science and technology leading pharmaceutical group based on the modernization and industrialization of traditional Chinese medicine, supported by high-tech drugs, which adheres to the R & D, production and sales of traditional Chinese medicine as the main business, focuses on the development of children's drugs, elderly drugs and drugs for major and difficult diseases urgently needed in the market. At present, Jianmin group has successfully developed and developed a series of products represented by Longmu Zhuanggu granules, Jianmin Yanhou tablets, Jianpi Shengxue granules, Bentong capsules and manganning capsules, forming a spectacular "famous brand forest" of the group, which is sold all over the country and exported to Southeast Asia, European and American countries and regions. In recent years, the group has been awarded the titles of "national advanced quality and benefit enterprise", "national excellent enterprise in traditional Chinese medicine industry", "National May 1st Labor Award", etc., and is honored as "a banner for invigorating state-owned enterprises", and the "invigorating the people" trademark has also won the title of "China famous trademark". A Jianmin group based on traditional Chinese medicine industry and characterized by high and new technology is bound to make more brilliant achievements in the new century and compose a beautiful movement to revitalize traditional Chinese medicine.

本文链接: https://brand.waitui.com/f7f9487ec.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

江波龙:员工持股平台拟合计减持公司不超1.31%股份

36氪获悉,江波龙公告,龙熹一号、龙熹二号、龙熹三号、龙舰管理、龙熹五号(统称“员工持股平台”)合计持有公司16.53%股份,计划在2025年9月11日至12月10日期间通过集中竞价交易方式和大宗交易方式合计减持公司股份不超过548万股(不超过公司总股本的1.31%)。

2小时前

云南锗业:公司及鑫耀公司目前并无6英寸磷化铟晶片规模化量产的具体计划

36氪获悉,云南锗业发布股票交易异常波动公告,公司了解到,近期有国内研发机构发布了其在6英寸磷化铟外延生长工艺领域实现了技术突破相关事宜。就控股子公司鑫耀公司而言,在2-4英寸规格的磷化铟晶片量产后,为应对未来的市场需求,对更大尺寸的产品开展了研究开发,但从研发到规模化生产尚存在较大不确定性。公司及鑫耀公司目前并无6英寸磷化铟晶片规模化量产的具体计划,下一步在市场与需求风险、技术风险等可控的前提下,公司方会考虑相关计划,如有相关计划,公司会按规定进行公开披露。

2小时前

胜宏科技:向香港联交所递交H股发行并上市申请并刊发申请资料

36氪获悉,胜宏科技公告,公司已于2025年8月20日向香港联交所递交了发行境外上市股份(H股)并在香港联交所主板挂牌上市的申请,并于同日在香港联交所网站刊登了本次发行的申请资料。该申请资料为草拟版本,其所载资料可能会适时作出更新及修订。公司本次发行尚需取得相关政府机关、监管机构、证券交易所的批准、核准或备案。

2小时前

永辉超市:上半年净亏损2.41亿元

36氪获悉,永辉超市公告,公司上半年实现营业总收入299.48亿元,同比下降20.73%;净亏损2.41亿元,上年同期盈利2.75亿元。

2小时前

摩根大通与三菱日联接近达成220亿美元的得州数据中心融资协议

英国《金融时报》周三报道,摩根大通和日本三菱日联金融集团正就为得克萨斯州一个数据中心承销220亿美元贷款展开谈判。报道称,该规划中的园区将由Vantage Data Centers所有,这是一家由银湖资本和资产管理公司DigitalBridge 控股的数字基础设施企业。报道还指出,银湖资本和DigitalBridge将合计承诺30亿美元股权,助力该数据中心园区的建设。(新浪财经)

2小时前

本页详细列出关于健民龙牡的品牌信息,含品牌所属公司介绍,健民龙牡所处行业的品牌地位及优势。
咨询